TSH and free T4: the test that can reverse the meaning of a testosterone result
An untreated thyroid can make a total testosterone read high in a man who is androgen-deficient, or low in a man who is not. And the guidelines do not ask for it.
Thyroid disease belongs on a testosterone workup for two reasons. Hypothyroidism and testosterone deficiency produce the same complaints; and thyroid disease alters SHBG, the protein that binds most circulating testosterone, and so alters what a total testosterone number means.
Why it is on the panel
Fatigue, low libido, low mood, poor concentration and weight gain appear on both lists, and neither condition can be told from the other at the bedside. In the Colorado Thyroid Disease Prevalence Study of 25,862 people, symptoms were commoner in hypothyroid than euthyroid participants, but the authors stated that "individual symptom sensitivities were low." A cluster carries weight where a single symptom does not: seven or more newly changed symptoms gave a likelihood ratio of 8.7, two or fewer a likelihood ratio of 0.5 — the same shape as the symptom set used for testosterone deficiency.
The SHBG effect is the more consequential. A man with untreated thyrotoxicosis can present with a total testosterone that looks high while his bioavailable testosterone is genuinely low; a man with untreated hypothyroidism can present with one that looks low and normalises on levothyroxine alone. Read without knowing thyroid status, both mislead.
The yield is low. A man is roughly six times less likely than a woman to develop spontaneous hypothyroidism — 0.6 versus 3.5 per 1,000 per year in the twenty-year follow-up of the Whickham survey, which called the incidence of hyperthyroidism in men "negligible." No study reports what proportion of men evaluated for testosterone deficiency have thyroid disease instead, so the case for checking a TSH rests on the consequence of the miss and on interpretation rather than on prevalence.
What thyrotoxicosis does
The cleanest evidence is experimental: seven healthy lean men given low-dose T3 for 63 days in a metabolic unit.
| Measure | Baseline | After T3 | Change |
|---|---|---|---|
| Total testosterone | 18.5 nmol/L | 26.3 nmol/L | +42% |
| SHBG | 18.0 nmol/L | 44.9 nmol/L | +150% |
| Free testosterone | 142.8 pmol/L | 137.3 pmol/L | no change |
Induce thyroid hormone excess in a normal man and total testosterone rises by over 40% while free testosterone does not move — a small study, but an interventional design in healthy volunteers carries weight out of proportion to its size.
In clinical Graves' disease the magnitudes are larger and the free fraction becomes clinically important. In 25 men with active disease compared with 10 normal men: total testosterone 9.3 versus 5.4 ng/mL, SHBG 102.3 versus 19.0 nmol/L — more than five times the control mean — and bioavailable testosterone 1.7 versus 3.1 ng/mL, 45% lower. The authors concluded that bioavailable testosterone identified hypoandrogenism despite the high total, and semen abnormalities were near-universal.
The free fraction is where the sources diverge: two other within-subject series found calculated free testosterone unchanged while the non-SHBG-bound fraction fell. Bioavailable testosterone includes the albumin-bound fraction and falls as SHBG sequesters more, while the true free fraction is better defended.
Reversal is consistent: abnormalities corrected when men became euthyroid after radioiodine, SHBG fell on carbimazole to values not significantly different from controls, and in six men restudied after seven to nineteen months of euthyroidism about 85% of semen abnormalities had normalised.
What hypothyroidism does
The opposite, with a different pituitary signature. Hypothyroidism lowers SHBG and produces a hypogonadotropic pattern — low testosterone with LH and FSH that are not elevated, the same pattern produced by obesity, opioids, glucocorticoids and acute illness.
The best primary evidence is small and old. In ten men with primary hypothyroidism measured before and after levothyroxine, free testosterone rose from 161 to 315 pmol/L, approximately double, on thyroid hormone alone, with no androgen given and gonadotropins not elevated. No randomised trial of levothyroxine with testosterone as an endpoint exists; the corroboration is review-level statements that free testosterone is reduced in primary hypothyroidism and normalises on replacement.
Hypothyroidism can also raise prolactin through TRH stimulation, but in men prolactin is not consistently elevated except in longstanding severe disease.
What the guidelines ask for
The Endocrine Society's 2018 guideline names no thyroid test anywhere. Thyroid disease appears only in Table 2, as a modifier of SHBG: hypothyroidism among the conditions that decrease it, hyperthyroidism among those that increase it, with the instruction to measure free testosterone when SHBG is likely altered.
The AUA's 2018 guideline mentions neither thyroid nor SHBG. Its named endocrine adjuncts are LH, prolactin, estradiol, FSH, haemoglobin and haematocrit, and PSA over 40. The EAU guideline mentions thyroid hormone only as an exogenous drug that raises SHBG, and does not name thyroid disease as a modifier at all.
All three converge: thyroid status matters as an SHBG modifier that changes how a total testosterone should be read, and none makes TSH a routine part of the workup. Checking one is a clinical judgement rather than a guideline requirement.
Reading the TSH itself
Three problems compound in the reference interval. The upper limit is disputed by two papers published back to back in the same 2005 issue of the Journal of Clinical Endocrinology and Metabolism. The case for lowering it to 2.5: more than 95% of normal individuals sit below 2.5 mIU/L, and older reference populations contained undiagnosed disease. The case against: in the NHANES III reference group of 14,333 people with no known thyroid disease and no antibodies, an additional 9.7% — about 20.6 million Americans — sit in the 2.5 to 4.5 band, and most people with thyroid autoimmunity have a TSH below 2.5. Both readings use the same data.
TSH drifts upward with age, physiologically. In people without thyroid disease, the proportion with a TSH above 2.5 rises from 10.6% at ages 20 to 29 to 40% at 80 and over, and the 97.5th centile from 3.56 to 7.49 mIU/L; seventy percent of older people with a TSH above 4.5 are inside their own age-specific range. The men evaluated for testosterone deficiency are the men in whom that drift occurs.
Assays disagree by more than the disputed band. Before international harmonisation the 97.5th percentile differed by 2.13 mIU/L across fourteen commercial platforms, and by 0.77 after recalibration, so a man could be subclinically hypothyroid at one laboratory and normal at another with identical serum.
The counter-argument to a population range is genuine. Sixteen healthy men sampled monthly for a year each varied around a distinct individual set point, with an individual's 95% interval about half the width of the group's and an index of individuality of 0.49; the authors concluded that "a test result within laboratory reference limits is not necessarily normal for an individual." The same paper found the difference needed for 95% confidence in a real change averaged 0.75 mIU/L. Those figures license serial measurement in one man on one assay, not the reading of a single value as a deviation from a set point never measured.
Treating a mildly raised TSH
The question that actually arises — fatigue, a TSH of 5, a normal free T4 — has been tested well. TRUST randomised 737 adults aged 65 and over with persisting subclinical hypothyroidism (TSH 4.60 to 19.99, normal free T4) to levothyroxine or placebo, double-blind with mock dose adjustment. TSH fell from 6.40 to 3.63 against 5.48 on placebo. Against a minimum clinically important difference of 9 points, the between-group differences on the two co-primary outcomes were 0.0 (95% CI −2.0 to 2.1) for hypothyroid symptoms and 0.4 (−2.1 to 2.9) for tiredness, with no benefit on any secondary outcome. Read as intervals rather than point estimates, TRUST excluded a clinically important benefit rather than merely failing to find one.
A prespecified secondary analysis addressed the most symptomatic participants. Among them, the levothyroxine group improved by 12.3 points on symptoms and 8.9 on tiredness; the placebo group improved by 10.4 and 10.9. The adjusted between-group differences were −2.0 (p=0.27) and 0.0 (p=0.99), with no interaction by baseline symptom burden. They improved well past the threshold for a meaningful change, on placebo, which is why uncontrolled before-and-after experience is so persuasive here and so unreliable.
A meta-analysis of 21 randomised trials in 2,192 adults, across all adult ages, agrees: quality of life SMD −0.11 (95% CI −0.25 to 0.03), thyroid-related symptoms SMD 0.01 (−0.12 to 0.14). None of this touches overt hypothyroidism — a raised TSH with a low free T4 — which is an undisputed treatment indication, and no trial reports a young-male subgroup.
How the result changes the reading
An unexpectedly high total testosterone in a symptomatic man puts thyrotoxicosis on the list alongside the commoner SHBG-raising states: age, HIV, cirrhosis or hepatitis, anticonvulsants, exogenous estrogen. A low total testosterone with LH and FSH that are not elevated puts untreated hypothyroidism among the reversible causes, alongside obesity, opioids, glucocorticoids, sleep apnoea and acute illness. Where SHBG is likely abnormal, free or bioavailable testosterone is the measurement to use — the one point every major guideline supports.
Thyroid disease is corrected first and the testosterone re-measured afterwards; one group recommended postponing specific treatment for erectile dysfunction until at least six months after euthyroidism, and the same logic applies with more force before committing a man to lifelong testosterone therapy. Which pattern fits a particular man is the substance of an individual assessment at the practice.
Questions patients ask
My total testosterone is high, so my hormones are fine.
An unexpectedly high total testosterone in a symptomatic man is one of the few patterns that should raise the question of thyrotoxicosis.
What the evidence showsIn 25 men with active Graves' disease, total testosterone averaged 9.3 ng/mL against 5.4 in controls, while SHBG was more than five times higher and bioavailable testosterone was 45% lower, at 1.7 versus 3.1 ng/mL. The authors concluded that bioavailable testosterone identified hypoandrogenism despite the high total. Experimentally, 63 days of low-dose T3 in healthy men raised total testosterone 42% and SHBG 150% with no change in free testosterone.
What remains uncertainWhat happens to the true free fraction. Two other series found calculated free testosterone unchanged in hyperthyroid men.
Bottom lineA high total testosterone is not self-explanatory. When it does not fit the clinical picture, what is binding it needs checking.
Mixed — Strong on the SHBG effect, Mixed on free testosterone
My testosterone is low, so I need testosterone.
Sometimes a low testosterone needs treatment of something else.
What the evidence showsIn ten men with primary hypothyroidism, free testosterone approximately doubled, from 161 to 315 pmol/L, on levothyroxine alone with no androgen given. Gonadotropins were not elevated — the hypogonadotropic pattern. The same reversibility is documented for thyrotoxicosis in the other direction, with about 85% of semen abnormalities normalising after seven to nineteen months of euthyroidism.
What remains uncertainThe magnitude. Ten men, uncontrolled, before and after; no randomised trial exists.
Bottom lineA low testosterone with non-elevated LH and FSH deserves a cause rather than a prescription, and thyroid disease sits on that differential alongside obesity, opioids, glucocorticoids and sleep apnoea.
Mixed — Moderate on direction, Limited on magnitude
The guidelines say to check my thyroid when checking testosterone.
They do not.
What the evidence showsThe Endocrine Society's 2018 guideline names no thyroid test anywhere; thyroid disease appears only in its table of SHBG modifiers, with the instruction to measure free testosterone when SHBG is likely altered. The AUA's 2018 guideline mentions neither thyroid nor SHBG. The EAU mentions thyroid hormone only as a drug that raises SHBG.
What remains uncertainNothing about the documents. What is unstudied is whether routine thyroid testing in this population changes any outcome.
Bottom lineChecking a TSH here is a clinical judgement about symptom overlap and interpretation rather than a guideline requirement.
Strong
My TSH is 3.2, which is in range but not optimal, and that is why I am tired.
There is a real argument underneath this, and it does not reach that conclusion.
What the evidence showsAbout 9.7% of people with no thyroid disease — roughly 20.6 million Americans — sit between 2.5 and 4.5. Forty percent of people over 80 without thyroid disease have a TSH above 2.5, and the 97.5th centile rises from 3.56 to 7.49 mIU/L between the third and ninth decades. Assay platforms differed by up to 2.13 mIU/L at the upper reference limit before harmonisation, more than the entire disputed band. And when TSH values averaging 6.40 were randomised to correction, symptom and tiredness scores did not improve.
What remains uncertainThe counter-argument is genuine. The index of individuality for TSH is 0.49, so a population range is a blunt instrument for one person, and in men a raised TSH carries an odds ratio of 44 for developing overt hypothyroidism over twenty years, rising to 173 with positive antibodies. A TSH of 3.5 in a man is not meaningless.
Bottom lineIt is a prognostic signal worth documenting, repeating and checking antibodies against. The evidence does not support the further step from prognostic signal to symptom explanation to treatment indication.
Moderate
Treating my borderline thyroid will fix the fatigue.
It was tested properly, and it did not.
What the evidence showsTRUST randomised 737 adults aged 65 and over with a TSH between 4.60 and 19.99 and a normal free T4. Levothyroxine lowered TSH from 6.40 to 3.63. Against a threshold of 9 points for a meaningful change, the between-group differences were 0.0 (95% CI −2.0 to 2.1) for symptoms and 0.4 (−2.1 to 2.9) for tiredness. In the most symptomatic participants, the levothyroxine group improved by 12.3 and 8.9 points and the placebo group by 10.4 and 10.9. A meta-analysis of 21 trials in 2,192 adults found quality of life at SMD −0.11 (−0.25 to 0.03).
What remains uncertainNo trial reports a young-male subgroup, and TRUST enrolled people over 65. Overt hypothyroidism, a raised TSH with a low free T4, is a different question and a clear treatment indication.
Bottom lineThe most symptomatic patients got substantially better on placebo, which is why personal before-and-after experience is so convincing here and so unreliable.
Strong
Adding T3 or desiccated thyroid would help where levothyroxine did not.
The randomised symptom evidence is null, and nothing has been tested on testosterone at all.
What the evidence showsA meta-analysis of 11 randomised trials in 1,216 patients comparing T4 plus T3 against T4 alone found no difference in fatigue (SMD −0.12, 95% CI −0.33 to 0.09), depression, anxiety, quality of life, bodily pain, weight or lipids, and no difference in adverse events. The American Thyroid Association concluded that levothyroxine should remain the standard of care and found no consistently strong evidence for the superiority of combination therapy or thyroid extract.
What remains uncertainThe ATA framed this as insufficient evidence rather than proven absence of benefit and listed long-term combination trials as a research need. A 2019 survey found liothyronine prescribing increasing over time. No study has tested whether adding T3 or desiccated thyroid raises testosterone or improves the symptoms of testosterone deficiency.
Bottom lineTreating diagnosed disease and pushing a normal TSH toward a preferred number are different interventions, and only the first is supported.
Mixed — Moderate that combination therapy does not outperform levothyroxine, Unsupported for any effect on testosterone
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
Our endocrinologists evaluate low testosterone in La Jolla, La Mesa and Poway: low testosterone care at Diabetes & Endocrine Specialists.


